Cargando…

During development, 17alpha-estradiol is a potent estrogen and carcinogen.

Neonatal administration of estradiol-17beta (E2-17beta) increases the nuclear DNA content in the mouse reproductive tract. Similar responses have been demonstrated for synthetic estrogens such as diethylstilbestrol. One of the questions raised regarding environmental estrogens such as organochlorine...

Descripción completa

Detalles Bibliográficos
Autores principales: Hajek, R A, Robertson, A D, Johnston, D A, Van, N T, Tcholakian, R K, Wagner, L A, Conti, C J, Meistrich, M L, Contreras, N, Edwards, C L, Jones, L A
Formato: Texto
Lenguaje:English
Publicado: 1997
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1469906/
https://www.ncbi.nlm.nih.gov/pubmed/9167998
_version_ 1782127709782016000
author Hajek, R A
Robertson, A D
Johnston, D A
Van, N T
Tcholakian, R K
Wagner, L A
Conti, C J
Meistrich, M L
Contreras, N
Edwards, C L
Jones, L A
author_facet Hajek, R A
Robertson, A D
Johnston, D A
Van, N T
Tcholakian, R K
Wagner, L A
Conti, C J
Meistrich, M L
Contreras, N
Edwards, C L
Jones, L A
author_sort Hajek, R A
collection PubMed
description Neonatal administration of estradiol-17beta (E2-17beta) increases the nuclear DNA content in the mouse reproductive tract. Similar responses have been demonstrated for synthetic estrogens such as diethylstilbestrol. One of the questions raised regarding environmental estrogens such as organochlorines is whether they are potent enough to result in abnormal changes such as those demonstrated by both natural and synthetic estrogens. To test this hypothesis, female BALB/c mice were treated neonatally (days 1-5) with either E2-17beta or estradiol-17alpha (E2-17alpha), an inactive stereoisomer in adult reproductive tissues. We also proposed whether neonatal administration of (E2-17alpha) was tumorigenic and whether the effects were age dependent. To answer these questions, one set each of 10 day-old treated and control mice received short-term secondary administration of E2-17beta, E2-17alpha, or cholesterol. Cervicovaginal tracts from intact BALB/c mice were examined histologically and by flow cytometry at 70 days of age and by histology alone at 18 to 22 months of age. The results include several important findings: a) like E2-17beta, neonatal E2-17alpha treatment induced persistent vaginal cornification, hypospadias, vaginal concretions, and hyperproliferation in nearly 100% of the animals regardless of the secondary treatment for most groups; b) neonatal E2-17alpha treatment increased the nuclear DNA content of cervicovaginal epithelium at one-half both the level (mean DNA index of 1.02 vs 1.04) and incidence (22 vs 46% of the animals) of E2-17beta; c) short-term secondary treatment with E2-17alpha, unlike E2-17beta, did not significantly augment the increase in DNA content (13% for E2-17alpha vs 37 and 56% for control and E2-17beta, respectively); and d) neonatal administration with E2-17alpha induced adenosquamous tumors in the reproductive tract in 25% of the animals. Therefore, the biological effects (estrogenic potency) of E2-17alpha may be age dependent.
format Text
id pubmed-1469906
institution National Center for Biotechnology Information
language English
publishDate 1997
record_format MEDLINE/PubMed
spelling pubmed-14699062006-06-01 During development, 17alpha-estradiol is a potent estrogen and carcinogen. Hajek, R A Robertson, A D Johnston, D A Van, N T Tcholakian, R K Wagner, L A Conti, C J Meistrich, M L Contreras, N Edwards, C L Jones, L A Environ Health Perspect Research Article Neonatal administration of estradiol-17beta (E2-17beta) increases the nuclear DNA content in the mouse reproductive tract. Similar responses have been demonstrated for synthetic estrogens such as diethylstilbestrol. One of the questions raised regarding environmental estrogens such as organochlorines is whether they are potent enough to result in abnormal changes such as those demonstrated by both natural and synthetic estrogens. To test this hypothesis, female BALB/c mice were treated neonatally (days 1-5) with either E2-17beta or estradiol-17alpha (E2-17alpha), an inactive stereoisomer in adult reproductive tissues. We also proposed whether neonatal administration of (E2-17alpha) was tumorigenic and whether the effects were age dependent. To answer these questions, one set each of 10 day-old treated and control mice received short-term secondary administration of E2-17beta, E2-17alpha, or cholesterol. Cervicovaginal tracts from intact BALB/c mice were examined histologically and by flow cytometry at 70 days of age and by histology alone at 18 to 22 months of age. The results include several important findings: a) like E2-17beta, neonatal E2-17alpha treatment induced persistent vaginal cornification, hypospadias, vaginal concretions, and hyperproliferation in nearly 100% of the animals regardless of the secondary treatment for most groups; b) neonatal E2-17alpha treatment increased the nuclear DNA content of cervicovaginal epithelium at one-half both the level (mean DNA index of 1.02 vs 1.04) and incidence (22 vs 46% of the animals) of E2-17beta; c) short-term secondary treatment with E2-17alpha, unlike E2-17beta, did not significantly augment the increase in DNA content (13% for E2-17alpha vs 37 and 56% for control and E2-17beta, respectively); and d) neonatal administration with E2-17alpha induced adenosquamous tumors in the reproductive tract in 25% of the animals. Therefore, the biological effects (estrogenic potency) of E2-17alpha may be age dependent. 1997-04 /pmc/articles/PMC1469906/ /pubmed/9167998 Text en
spellingShingle Research Article
Hajek, R A
Robertson, A D
Johnston, D A
Van, N T
Tcholakian, R K
Wagner, L A
Conti, C J
Meistrich, M L
Contreras, N
Edwards, C L
Jones, L A
During development, 17alpha-estradiol is a potent estrogen and carcinogen.
title During development, 17alpha-estradiol is a potent estrogen and carcinogen.
title_full During development, 17alpha-estradiol is a potent estrogen and carcinogen.
title_fullStr During development, 17alpha-estradiol is a potent estrogen and carcinogen.
title_full_unstemmed During development, 17alpha-estradiol is a potent estrogen and carcinogen.
title_short During development, 17alpha-estradiol is a potent estrogen and carcinogen.
title_sort during development, 17alpha-estradiol is a potent estrogen and carcinogen.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1469906/
https://www.ncbi.nlm.nih.gov/pubmed/9167998
work_keys_str_mv AT hajekra duringdevelopment17alphaestradiolisapotentestrogenandcarcinogen
AT robertsonad duringdevelopment17alphaestradiolisapotentestrogenandcarcinogen
AT johnstonda duringdevelopment17alphaestradiolisapotentestrogenandcarcinogen
AT vannt duringdevelopment17alphaestradiolisapotentestrogenandcarcinogen
AT tcholakianrk duringdevelopment17alphaestradiolisapotentestrogenandcarcinogen
AT wagnerla duringdevelopment17alphaestradiolisapotentestrogenandcarcinogen
AT conticj duringdevelopment17alphaestradiolisapotentestrogenandcarcinogen
AT meistrichml duringdevelopment17alphaestradiolisapotentestrogenandcarcinogen
AT contrerasn duringdevelopment17alphaestradiolisapotentestrogenandcarcinogen
AT edwardscl duringdevelopment17alphaestradiolisapotentestrogenandcarcinogen
AT jonesla duringdevelopment17alphaestradiolisapotentestrogenandcarcinogen